Many states have moved to enact mandatory pharmaceutical price and/or financial disclosure laws that are intended to increase price transparency to address concerns about prescription drug costs. These laws are intended to lead to increased pharmaceutical market competition. Ultimately, federal and state regulators view these requirements as an initial step in controlling the cost of pharmaceuticals.
As of early 2020, 19 states have specific regulations that require varying degrees of price reporting or financial disclosure requirements. There are also 19 states considering additional transparency legislation. No two states are alike, and there is a wide variety of mandated notification rule sets. States have already started to be aggressive in levying fines for non-compliance, increasing the importance of staying on top of diverse state requirements. Learn more by reading our latest white paper.